Filter by tags: Research reactor CANDU reactor Clear all tag filters
5 news articles found
Medical isotopes are radioactive substances used in various diagnostic and therapeutic procedures to treat various types of cancers and other conditions. They are essential for modern medicine, allowing physicians to visualise and target specific organs, tissues and cells in a patient’s body.
Over more than a decade, personalised medicine using nuclear techniques has been gaining pace, allowing doctors to tailor therapies and treatments to the specific needs and physiology of a patient, and to avoid harm to healthy organs or tissues.
According to Sven Van den Berghe, chief executive of Belgium-based isotope producer PanTera, one technique that has seen significant advances is known as theranostics – the term used to describe the combination of using one radioactive drug to diagnose and a second to deliver therapy to treat the main tumour and any metastatic tumours.
- Source: Nucnet
- Date: Friday, 14 April 2023
- Original article: nucnet.org/news/sector-aims-to-tackle-isotope-supply-problems-as-excitement-grows-over-targeted-therapies-4-4-2023
Canada’s Saskatchewan Research Council has announced that its Safe Low Power Kritical Experiment (Slowpoke) research reactor has been defuelled in preparation for its decommissioning, and the fuel has been transported to the USA without incident.
- Source: NEI Magazine
- Date: Wednesday, 02 October 2019
- Original article: neimagazine.com/news/newssaskatchewan-slowpoke-reactor-ready-for-decommissioning-7431063
Ahead of its decommissioning, the low-enriched uranium fuel has been removed from the Saskatchewan Research Council's (SRC's) Slowpoke-2 research reactor in Saskatoon and transported to the USA.
- Source: World Nuclear News
- Date: Saturday, 28 September 2019
- Original article: world-nuclear-news.org/Articles/Defuelling-completed-at-Canadian-research-reactor
Canadian Nuclear Laboratories (CNL) announced on 2 April that isotope production reactor the National Research Universal (NRU) at the Chalk River site had been permanently shut down. It will now be placed into a "state of storage" prior to decommissioning. The reactor, which produced about 40% of world supply of molybdenum-99 (Mo-99), ceased production in October 2016, since when it has remained on standby "in case of a significant shortage which could not be mitigated by other means". Research reactors in Australia, Europe, Russia and South Africa have since met demand.
- Source: NEI Magazine
- Date: Friday, 06 April 2018
- Original article: neimagazine.com/news/newscanada-permanently-closes-nru-research-reactor-6107149
Candu Energy, a subsidiary of Canada's SNC-Lavalin, has been awarded a contract by the University of Alberta to lead decommissioning of its Safe Low Power Kritical Experiment (Slowpoke) research reactor. Under the "multi-million dollar" contract, which was awarded through a public procurement process, SNC-Lavalin will perform and manage the decommissioning work, including waste management. In addition to providing the necessary tooling, equipment and training for the work, SNC-Lavalin will also deliver project, training and support documentation. The Slowpoke research reactor design was developed by Atomic Energy of Canada Limited (AECL) in the 1960s. AECL's former Candu Reactor Division was sold to Candu Energy in 2011.
- Source: NEI Magazine
- Date: Tuesday, 12 April 2016
- Original article: neimagazine.com/news/newsslowpoke-reactor-at-alberta-university-to-be-decommissioned-4862234